 |
Partners' Directory |
| Home Search Join the Partnership Login | |
| Contact | General | Specializations in Countries | Contribution to the Global Plan | Declaration |
View this partner's profile
Organization Contact Information | |
| Name: | Q Biotechnologies Ltd |
| Street 1: | S12 Sparkhouse Building, University of Lincoln |
| Street 2: | Ropewalk |
| City: | Lincoln |
| Province: | Lincolnshire |
| Post Code: | LN6 7DQ |
| Country: | United Kingdom of Great Britain and Northern Ireland |
| Phone: | 01522 837220 |
| Organization Email: | claire.bryan@qtechnologiesgroup.com |
| Web Site: | http://www.qtechnologiesgroup.com |
| Other Online Presence: | |
|
|
||||||||||||||||||||||||||||
General Information | |
| Board Constituency: | Private sector |
| Is your organization legally registered in your country: | Yes |
| If yes, please enter your registration number: | |
| Organization Type - Primary: | Private Sector |
| Organization Type - Secondary: | Company |
| Organization Description: | |
| Q Biotechnologies Ltd is a progressive organisation that develops, manufactures and distributes under exclusive license, products for disease prevention. Our portfolio includes rapid and accurate testing, persistent surface and skin disinfectants and capital equipment. We are interested in TB because we have international distributors of our persistent SiQuat Q Shield. This has been used in South Africa to prevent TB/HIV and fungal infections in mine workers. We intend to conduct further research in country on early diagnosis to prevent the spread of infection. We would like to get involved with national and international projects for prevention, early detection and sharing best practice. Our SiQuat is currently being used in hospital studies to prevent SSIs, we actively share this data to encourage a new emphasis on prevention rather than cure. Dr Kemp is involved with leading microbiologists in the NHS, to write a new environmental cleaning directive which we would hope can be incorporated into every setting to reduce infection rates. |
|
| Do you know about the UNHLM declaration: | |
Specializations / Areas of Work | |
|
Provision of drugs, diagnostics and commodities Research and Development Technical Assistance |
Other Organization Information | |
| Total number of staff in your organization: | 1 - 5 |
| Number of full-time staff who are directly involved with TB: | 1 - 5 |
| Number of part-time staff who are directly involved with TB: | 0 |
| Number of volunteers who are directly involved with TB: | 0 |
| How did you hear about the Stop TB Partnership: | Media |
| If you were informed or referred by another partner of the Stop TB Partnership please tell us who: | |
| Why do you wish join the Stop TB Partnership: | Involvement in Stop TB Working Groups |
| Are you a member of a Stop TB national partnership: | No |
| Are you in contact with your national TB programme: | No |
| Please tell us how your organization is contributing to your country's national TB control plan: | |
| We do not currently contribute to the national control plan, we are actively looking for opportunities to do this. | |
Geographical Reach | |
| Which country is your headquarters located in: | United Kingdom of Great Britain and Northern Ireland |
| Which countries do you do operate in: (This includes countries you are conducting activities in) |
Australia China Malaysia Norway South Africa Thailand United Kingdom of Great Britain and Northern Ireland United States of America |
Contribution | |
| Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below: | |
|
TB-HIV: We will run further testing on TB with a view to campaign for the use of persistent products to prevent infection. Raising awareness and sharing best practice in surface disinfection and decontamination is our goal to prevent people from getting TB. New Diagnostics: Our portfolio includes rapid and accurate testing. Research: We will be actively looking for opportunities to research effectiveness of using persistent products over non persistent to prevent infection. |
|
Declaration | |
| Declaration of interests: No conflicts of interest were delacred. | |
| Application date: | November 22, 2017 |
| Last updated: | November 29, 2017 |